Market Size Estimation
Both top-down and bottom-up approaches have been used to estimate and validate the size of the epigenetics market and its dependent submarkets. These methods were also used extensively to determine the extent of various sub-segments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and demand have been identified through extensive secondary research, and their market share has been determined through both primary and secondary research.
- The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Expected Revenue Growth Analysis:
The Epigenetics Market is projected to reach USD 1,605.7 million by 2022 from an estimated USD 854.0 million in 2017, at a CAGR of 13.5% during the forecast period.
Download PDF Brochure:
Key Factors Driving Market Growth:
The growth in epigenetics market is primarily attributed to decreasing sequencing costs, increasing research activity, funding for epigenetics research, rising prevalence of cancer and growing applications of epigenetics in non-oncology diseases. Expanding application areas of epigenetics in non-oncology diseases, personalized medicine, and target therapy are expected to provide growth opportunities for players operating in the market in the coming years.
Kits Segment Accounted for the Largest Share of the Global Market, by Product
On the basis of product, the kits segment accounted for the largest share of the Global Epigenetics Market in 2016. This can be attributed to the fact that a large number of kits are used in various epigenetic techniques. The rising prevalence of a number of diseases, increasing R&D spending, and increased government funding for life science research are the other factors expected to support DNA methylation market growth.
Among the Application Segments, Oncology Dominated the DNA Methylation Market
Based on application, the oncology segment accounted for the largest share of the Epigenetics Market in 2016. The large share of this segment can be attributed to the rising prevalence of cancer and the increasing number of research-related activities.
DNA Methylation Segment Dominated the Epigenetics Market, by Technology
On the basis of technology, the Epigenetics Market is segmented into DNA methylation, histone modifications, and other technologies (includes non-coding RNA and chromatin remodeling). The DNA methylation segment accounted for the largest share of the Global Epigenetics Market in 2016. The large share of this segment is attributed to the increasing incidence of cancer and the ability of this technique to study different types of cancer with quality outcomes.
North America Dominated the Global Epigenetics Industry
North America accounted for the largest share of the DNA Methylation Market in 2016, followed by Europe. Increase in epigenetics research activities, favorable government funding initiatives, high R&D expenditure, rising incidence of various diseases, and the presence of key players in the region are the key factors driving the growth of the Epigenetics Industry in North America.
Request Sample Report:
The major players in the Global Epigenetics Market are Illumina (US), Thermo Fisher (US), Diagenode (Belgium), QIAGEN (US), Merck Millipore (US), Abcam (UK), Active Motif (US), New England Biolabs (US), Agilent (US), Zymo Research (US), PerkinElmer (US), and Bio-Rad (US).